News
-
-
-
COMMUNIQUÉ DE PRESSE
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
Protagonist Therapeutics named one of Fast Company's Most Innovative Companies 2025 for pioneering peptide-based therapeutics. Recognized for groundbreaking work in drug development -
-
-
COMMUNIQUÉ DE PRESSE
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
Protagonist Therapeutics, Inc. announces positive topline results from ANTHEM-UC Phase 2b study of icotrokinra in ulcerative colitis, meeting primary endpoint. Results indicate high clinical response and remission rates -
-
-
COMMUNIQUÉ DE PRESSE
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
Protagonist Therapeutics announces new data on icotrokinra in Phase 3 studies for moderate-to-severe plaque psoriasis. Launching first head-to-head study vs. ustekinumab -
